Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025

Core Insights - Krystal Biotech, Inc. will report its second quarter 2025 financial results on August 4, 2025, before U.S. market opens [1] - A conference call and webcast will be held on the same day at 8:30 am ET to discuss the financial results and provide a business update [1] Company Overview - Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on genetic medicines for diseases with high unmet medical needs [3] - The company's first commercial product, VYJUVEK, is the first-ever redosable gene therapy approved in the U.S., Europe, and Japan for dystrophic epidermolysis bullosa [3] - The company is advancing a pipeline of investigational genetic medicines across various fields including respiratory, oncology, dermatology, ophthalmology, and aesthetics [3]